Abzena invests $60 million to expand cGMP manufacturing capacity
New facility boosts manufacturing services for biologic projects
Abzena, a contract provider of integrated services for biologics and bioconjugates, has invested $60 million into a new facility for late phase and commercial current good manufacturing practice (cGMP) production.
The new 50,000 square foot ‘Lusk’ facility at the company’s site in San Diego houses a process development laboratory and two new cGMP manufacturing cleanrooms for 500L and 2,000L scale in Sartorius single use bioreactors. The facility also houses a good manufacturing practice warehouse and analytical development and quality control laboratories.
The facility will enable the company to deliver Phase I to commercial manufacturing services for biologic projects, according to Abzena.
“Until now our other San Diego site has been focused primarily on development and manufacture of Phase I and II clinical trial materials,” saidMatt LeClair, senior VP, who added that the expansion will allow the company to provide project integration as customers move into Phase III and ultimately commercial manufacture.
The new facility, which received its manufacturing license from the California Food and Drug Branch, has added 125 new positions within the company.
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.
